TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
63.38
+3.55 (5.93%)
At close: Nov 9, 2026, 4:00 PM EST
63.51
+0.13 (0.21%)
Pre-market: Nov 10, 2026, 7:44 AM EST
TG Therapeutics Revenue
TG Therapeutics had revenue of $259.94M in the quarter ending September 30, 2026, with 60.74% growth. This brings the company's total for the last twelve months to $897.76M, up 68.78% year-over-year. In the year 2025, TG Therapeutics had annual revenue of $616.29M with 87.32% growth. That makes TG Therapeutics the 8,131st largest company in the world by revenue and 1,862nd in the United States.
Revenue (ttm)
$897.76M
Revenue Growth
+68.78%
P/S Ratio
10.01
Revenue / Employee
$2,250,033
Employees
399
Market Cap
8.99B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full TG Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 616.29M | 287.28M | 87.32% |
| Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
| Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
| Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
| Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
| Dec 31, 2020 | 152.00K | - | - |
| Dec 31, 2019 | 152.00K | - | - |
| Dec 31, 2018 | 152.00K | - | - |
| Dec 31, 2017 | 152.00K | - | - |
| Dec 31, 2016 | 152.00K | -381.00 | -0.25% |
| Dec 31, 2015 | 152.38K | - | - |
| Dec 31, 2014 | 152.38K | - | - |
| Dec 31, 2013 | 152.38K | 133.33K | 699.98% |
| Dec 31, 2012 | 19.05K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Madrigal Pharmaceuticals | 1.43B |
| Corcept Therapeutics | 963.65M |
| Arrowhead Pharmaceuticals | 669.50M |
| Protagonist Therapeutics | 551.69M |
| Krystal Biotech | 470.03M |
| Twist Bioscience | 431.80M |
| Rhythm Pharmaceuticals | 280.75M |
| ImmunityBio | 165.79M |
TGTX News
- 17 hours ago - TG’s Briumvi nearing blockbuster status, says TD Cowen - TheFly
- 23 hours ago - TG Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 23 hours ago - TG Therapeutics Earnings release: Q3 2026 - Filings
- 23 hours ago - TG Therapeutics Quarterly report: Q3 2026 - Filings
- 1 day ago - TG Therapeutics reports Q3 EPS 35c, consensus 26c - TheFly
- 1 day ago - TG Therapeutics sees cash runway ‘sufficient to fund’ business - TheFly
- 1 day ago - TG Therapeutics raises FY26 revenue target to $1B, consensus $960.26M - TheFly
- 1 day ago - TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance - Business Wire